An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Zai Lab (ZLAB) will announce its first quarter 2024 financial results and recent corporate updates on May 8, 2024. The company will host a conference call and webcast on May 9, 2024, at 8:00 a.m. ET (8:00 p.m. HKT) for investors and analysts to discuss the results.
Positive
None.
Negative
None.
- Company to Host Conference Call and Webcast on May 9, 2024, at 8:00 a.m. ET (8:00 p.m. HKT)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the first quarter of 2024 and recent corporate updates, after the closing of the U.S. equity markets on Wednesday, May 8, 2024. The Company will host a live conference call and webcast on Thursday, May 9, 2024, at 8:00 a.m. ET (8:00 p.m. HKT).
Conference Call and Webcast Information
Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call.
All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-in details will be in the confirmation email which the participant will receive upon registering.
A replay will be available shortly after the call and can be accessed by visiting the Company's website.
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious disease, and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.
For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.
Zai Lab will announce its first quarter 2024 financial results on May 8, 2024.
The ticker symbol for Zai Lab is ZLAB.
The conference call and webcast to discuss the financial results are scheduled for May 9, 2024, at 8:00 a.m. ET (8:00 p.m. HKT).
Participants can access the live webcast by visiting Zai Lab's website at http://ir.zailaboratory.com and registering in advance of the conference call.
Yes, a replay will be available shortly after the call and can be accessed by visiting Zai Lab's website.
zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve
